 |
|
The Use of Chlorothiazide in the Nephrotic Syndrome
G. E. BURCH, M.D.;
H. AUBREY WHITE, Jr., M.D.
AMA Arch Intern Med. 1959;103(3):369-380.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings. |
|
|
|
The new diuretic agent, chlorothiazide (6-chloro-7-sulfamyl-1,2,4-benzot benzothiadiazine-1,1-dioxide),* is useful in the treatment of many clinical disorders, including congestive heart failure, cirrhosis, nephrosis, essential hypertension, premenstrual edema, and toxemia of pregnancy.1-9 Among its various clinical advantages are (1) remarkable effectiveness when administered orally; (2) prompt diuretic action, consisting of water diuresis, natruresis, and chloruresis but only minimal kaluresis; (3) persistent activity and lack of tolerance until edema subsides; (4) antihypertensive action, and (5) minimal side-effects or toxic reactions.
Basic pharmacologic studies have demonstrated that chlorothiazide inhibits carbonic anhydrase in vitro but not significantly in vivo,2 and clinical trials in man indicate that its diuretic action is qualitatively similar to that of the mercurial diuretics. In short-term animal experiments,1 maximal diuresis was observed at 40 minutes after intravenous administration, with a total duration of effect of about 4 hours. The peak response after oral administration occurred at 4 hours,
. . . [Full Text PDF of this Article]
Author Affiliations
New Orleans
From the Department of Medicine, Tulane University, School of Medicine and Charity Hospital of Louisiana at New Orleans.
Footnotes
Submitted for publication Aug. 1, 1958.
Aided by Grants from Public Health Service (H143) and the Thibodeaux Research Foundation.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
|
